Hashimoto Y, Michihata N, Yamana H, et al. - Using the JMDC Claims Database (JMDC, Tokyo, Japan), 2005–2018, researchers conducted this retrospective, cohort study to explore the connection between exposure to intraocular pressure (IOP)–lowering medications during pregnancy and neonatal adverse outcomes. Data were obtained on pregnant women with glaucoma, including dispensation of any IOP-lowering medications, only prostaglandin analogues (PGs) and only beta-blockers, during the first trimester. Eight hundred twenty-six eligible women were identified, 91 (11%) of whom had received any IOP-lowering medications. The authors discovered that congenital anomalies (CA) occurred in 9.9% and 6.4%, preterm birth (PB) in 2.2% and 4.5%, low birth weight (LBW) in 9.9% and 6.0% and composite outcome in 17.6% and 13.3% of mothers with and without IOP-lowering drugs, respectively. During the first trimester, IOP-lowering medications were not significantly linked to rising in CA, PB or LBW. Only PGs and beta-blockers have had similar results.